Study: Drugs in rare pediatric disease priority review voucher program have similar revenue to brand drugs
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysPharmaceuticalsPriority review voucherProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)